纳斯达克摘牌后，美国OTC市场成中企赴美上市新选择

Core Viewpoint - The recent delisting of SPACs associated with Chinese companies has halted their plans for U.S. listings, highlighting the risks of the SPAC model and the unique value of the OTC market [1] Group 1: SPAC Delisting and Its Implications - Nasdaq delisted 13 securities on January 13, including three SPACs (Four Leaf, DT Cloud, AlphaTime) linked to Chinese companies, transferring them to the OTC market [1] - The delisting exposes the vulnerabilities of the SPAC model, particularly the reliance on the SPAC's continued listing status [4] - The case of Xiaoyu Tidata illustrates that even with stable business operations, a SPAC's delisting can abruptly halt the entire listing process [4] Group 2: Regulatory Changes and Challenges - New Nasdaq regulations effective January 17, 2026, will raise the minimum public float market value requirement from $5 million to $15 million and mandate that SPAC mergers must raise at least $25 million in public funds [4] - These regulatory changes create significant barriers for many small and medium-sized enterprises [4] Group 3: Advantages of the OTC Market - The OTC market offers a crucial buffer, allowing SPACs to continue merger transactions even after delisting from the main board [5] - OTC has lower financial requirements, with no strict profitability criteria and minimal annual fees ranging from a few thousand to $20,000 [6] - The listing process on the OTC market can be completed in 3-6 months, significantly faster than the 12-24 months required for a Nasdaq IPO [7] Group 4: Structured Compliance and Growth Opportunities - The OTC market features a four-tier compliance structure, catering to different stages of company development [8] - Companies already listed on domestic boards can issue ADRs on OTCQX without meeting stringent SEC registration requirements, facilitating exposure to U.S. investors [9] - The OTC market serves as a "golden stepping stone" for companies aiming to transition to Nasdaq or NYSE, with approximately 15% of Nasdaq-listed companies having previously grown on the OTC market [10] Group 5: Diverse Financing Options - The OTC market supports various financing methods, including private placements and convertible bonds, which are particularly suitable for light-asset companies in technology and biomedicine [11] - Companies can leverage the OTC market to access global financing while providing liquidity options for early investors [11] - The current delisting trend reinforces the need for Chinese companies to consider paths beyond the main board for U.S. listings [11]